Skip to main content
. 2023 Mar 17;12:e80768. doi: 10.7554/eLife.80768

Figure 2. Circulating ILC1lc expanded and characterized by FACS analysis.

(A) PBMCs activated by IL-18, IL-33 and IL-12 were sorted by FACS Aria and characterized by FACS analysis. ILC1lc markers were identified by the expression of CD127+, CD161+, c-KIT-, and CRTH2-, high levels of integrin α1 (CD49a) expression, combined with the absence of integrin α2 (CD49b) and transcription factors Eomeshi and T-betlo (B) unstimulated PBMCs (C) isotype controls. N=10 blood donors, 1.5 × 106 cells/blood donor, analysis was performed in triplicates from each of the blood donors. Following Shapiro-Wilk test, Student’s t-test, p<0.05.

Figure 2—source data 1. Quantitative data for circulating ILC1lc expanded and characterized by FACS analysis.

Figure 2.

Figure 2—figure supplement 1. Circulating ILC1lc expanded and characterized by FACS analysis.

Figure 2—figure supplement 1.

(A) PBMCs activated by IL-18, IL-33, and IL-12 were sorted by FACS Aria and characterized by FACS analysis. ILC1-like cell markers were identified by the expression of Eomes+, CXCR6+, CD200R+, IRF8-, Perforin-, CD16-, and NKP80 (B) IL-2 induced PBMCs (C) isotype controls. (D) expression of CD127+, CD161 +, and RORγt-. N=4 blood donors, 1.5 × 106 cells/blood donor, analysis was performed in triplicates from each of the blood donors. Following Shapiro-Wilk test, Student’s t-test, p<0.05.
Figure 2—figure supplement 2. Scheme demonstrating the isolation of ILC1lc, ILC2s, and ILC3s cells from PBMCs of healthy human volunteers.

Figure 2—figure supplement 2.